Thu, Apr 3, 9:01 PM (26 days ago)
**Summary of AccuStem Sciences, Inc. (ACUT) 2024 Annual Report** **Financial Performance:** - **Revenue:** $0 (no revenue generated). - **Net Income:** $(1,505,102) for 2024, $(2,050,664) for 2023 (consistent net losses). - **Operating Expenses:** $1,505,102 for 2024, $2,050,664 for 2023 (primarily research and development, and general and administrative costs). - **Earnings per Share:** $(0.13) for 2024, $(0.18) for 2023. **Strategic Overview:** - **Products:** Focus on MSC (MicroRNA Signature Classifier) for lung nodules and StemPrintER for breast cancer. - **Market Opportunity:** Estimated $6.3 billion annual revenue in the US. - **Competitive Landscape:** Faces competition from established and emerging diagnostic companies. **Future Outlook:** - **Milestones:** Achieved partnership with EmeritusDx for laboratory services. - **Regulatory:** Seeking CLIA certification for commercial testing. - **Expansion:** Plans to expand into other markets post-US launch. **Risk Factors:** - **Financial:** Significant net losses, reliance on additional funding. - **Operational:** Dependence on third-party services, regulatory uncertainties. - **Market:** Competition, reimbursement challenges, technological changes. **Financial Condition:** - **Cash Position:** $5,047 as of December 31, 2024 (insufficient for operations beyond April 2025). - **Funding:** Seeking additional equity or debt financing. - **Liquidity:** Negative cash flows from operations. **Market Position Changes:** - **Trading:** Listed on OTC Markets (OTCQB) under symbol "ACUT." - **Shareholders:** Approximately 510 holders of record as of March 31, 2025. **Management and Governance:** - **Board:** Five members, including CEO Wendy Blosser and four non-executive directors. - **Executive Compensation:** Key executives receive base salaries and potential bonuses tied to corporate milestones. **Conclusion:** AccuStem Sciences, Inc. is a clinical-stage diagnostics company focusing on oncology. Despite significant financial challenges and operational risks, the company aims to commercialize its proprietary tests, MSC and StemPrintER, with a strategic focus on regulatory approval and market expansion. The company's future success depends on securing additional funding, navigating regulatory pathways, and effectively managing competitive pressures.